

V.I. Technologies Incorporated

[View the current V.I. Technologies Incorporated Page on BioPortfolio.com](http://www.bioportfolio.com/biocorporate/10719-V.I.+Technologies+Incorporated.html)

(<http://www.bioportfolio.com/biocorporate/10719-V.I.+Technologies+Incorporated.html>)

Contact Details:

134 Coolidge Avenue

Watertown

MA

02472

United States of America

Tel: (617) 926-1551

Fax:

Email: info@vitechnologies.com

V.I. Technologies is a leading developer of a broad portfolio of blood products and systems which use its proprietary pathogen inactivation technologies. The Company's technologies are intended to address the risks of viral, bacterial and other pathogen contamination in blood products, including plasma, plasma derivatives, red blood cells and platelets. Viral inactivation processes have the potential to eliminate viruses that are enveloped by lipid membranes such as hepatitis B virus ("HBV"), hepatitis C virus ("HCV") and HIV, the virus that causes AIDS, and non-enveloped viruses such as hepatitis A virus ("HAV") and parvovirus and other known and unknown pathogens.

Recent Publications by V.I. Technologies Incorporated:



- [Development of models and detection methods for different forms of cytomegalovirus for the evaluation of viral inactivation agents.](#)
BACKGROUND: Cytomegalovirus (CMV) is transmitted by transfusion of... 18th October, 2006
V.I. Technologies, Inc., Watertown, Massachusetts, USA.- *Transfusion*. 2006 Sep;46(9):1580-8. ([DOI Direct Link](#))
- [Inactivation of Gram-negative and Gram-positive bacteria in red cell concentrates using INACTINE PEN110 chemistry.](#)
BACKGROUND AND OBJECTIVES: The risk of transfusion-transmitted bacterial... 30th March, 2005
V. I. Technologies, Inc., Watertown, MA 02472, USA.- *Vox Sang*. 2004 Oct;87(3):143-9. ([DOI Direct Link](#))
- [Induction of latent human cytomegalovirus by conventional gamma irradiation and prevention by treatment with INACTINE PEN110.](#)

- BACKGROUND AND OBJECTIVES: Two different leucocyte-inactivation...* 14th October, 2004
V. I. Technologies, Inc., Watertown, MA 02465, USA.- Vox Sang. 2004 Jul;87(1):1-9. ([DOI Direct Link](#))
- [Inactivation of protozoan parasites in red blood cells using INACTINE PEN110 chemistry.](#)
BACKGROUND: The transmission of parasites, including Babesia, plasmodia,... 3rd June, 2004
V.I. Technologies, Inc., Watertown, Massachusetts 02472, USA.- Transfusion. 2004 May;44(5):731-8. ([DOI Direct Link](#))
 - [Inactivation of mycoplasma species in blood by INACTINE PEN110 process.](#)
BACKGROUND: Mycoplasmas have been associated with multiple acute and... 24th March, 2004
V. I. Technologies, Inc., Watertown, Massachusetts 02472, USA.- Transfusion. 2004 Feb;44(2):286-93.
 - [Pathogen inactivation of RBCs: PEN110 reproductive toxicology studies.](#)
BACKGROUND: The novel PEN110 chemistry (INACTINE, V.I. Technologies)... 24th October, 2003
V.I. Technologies (VITEX), Watertown, Massachusetts 02472, USA.- Transfusion. 2003 Oct;43(10):1386-93.
 - [West Nile virus in blood: stability, distribution, and susceptibility to PEN110 inactivation.](#)
BACKGROUND: The outbreak of West Nile virus (WNV) is the most recent... 25th September, 2003
V.I. Technologies, Inc., Watertown, Massachusetts 02472, USA.- Transfusion. 2003 Aug;43(8):1029-37.
 - [Broad-spectrum virus reduction in red cell concentrates using INACTINE PEN110 chemistry.](#)
BACKGROUND AND OBJECTIVES: The risk of transmission of blood-borne... 12th July, 2003
V. I. Technologies, Inc., 134 Coolidge Avenue, Watertown, MA 02472, USA.- Vox Sang. 2002 Nov;83(4):313-23.
 - [Prevention of Yersinia enterocolitica, Pseudomonas fluorescens, and Pseudomonas putida outgrowth in deliberately inoculated blood by a novel pathogen-reduction process.](#)
BACKGROUND: Yersinia enterocolitica, Pseudomonas fluorescens, and P.... 25th April, 2003
V. I. Technologies, Inc., Watertown, Massachusetts, USA.- Transfusion. 2003 Feb;43(2):135-42.
 - [Inactivation of HIV in blood.](#)
BACKGROUND: The residual risk of HIV infection after HIV screening tests... 5th December, 2002
V.I. Technologies, Inc., 134 Coolidge Avenue, Watertown, MA 02472, USA.- Transfusion. 2002 Oct;42(10):1308-17.
 - [Photochemical decontamination of red blood cell concentrates with the silicon phthalocyanine PC 4 and red light.](#)
Various approaches are being developed for virus inactivation of red blood... 15th July, 2000
V.I. Technologies, Inc. (Vitex), New York, NY 10032, USA.- Dev Biol (Basel). 2000;102:149-55.

BioNews Results for V.I. Technologies Incorporated



- [New Worlds: Bats, belfries and brain function](#)
Jerusalem Post: Oct 4 2008 8:25PM Matching: v technologies
- [Get a Deep Insight into the World Biometrics Market](#)
IT Business Net: Oct 2 2008 5:02AM Matching: v technologies
- [Get a Deep Insight into the World Biometrics Market](#)
Interest!ALERT: Oct 2 2008 3:24AM Matching: v technologies
- [Emisphere Announces Publication of Independent Early-Stage Clinical Study on the Effects of Oral GLP-1 and PYY](#)
NewsBlaze: Oct 1 2008 12:56PM Matching: v technologies
- [DIARY - Western European Corporate events from Oct 01, 2008](#)
Forbes.com: Oct 1 2008 6:52AM Matching: v technologies

- [To Advance HIV-1 Integrase Inhibitor Program with a Major Pharmaceutical Company](#)
Therapeutics Daily: Sep 25 2008 3:42AM Matching: v technologies
- [Boston Scientific gets FDA approval for two drug-eluting stent systems - Update](#)
RTTNews.com: Sep 25 2008 2:15PM Matching: v technologies
- [DIARY - Western European Corporate events from Sep 25, 2008](#)
Forbes.com: Sep 25 2008 6:25AM Matching: v technologies
- [DIARY - Western European Corporate events from Sep 25, 2008](#)
FinanzNachrichten.de: Sep 25 2008 5:14AM Matching: v technologies
- [Emisphere Technologies, Inc. Q2 2008 Earnings Call Transcript](#)
Seeking Alpha: Sep 24 2008 8:29AM Matching: v technologies
- [Evident Technologies Announces Issuance of Key Patent for Semiconductor Nanocrystals Made From III-V Materials](#)
Genetic Engineering News: Sep 23 2008 3:10PM Matching: v technologies
- [Women for Women International Project Selected as Top 25 American Express Members Project](#)
EMedia Wire: Sep 23 2008 6:27PM Matching: v technologies
- [Biometrics review](#)
Hi-Tech Security Solutions: Sep 22 2008 3:03PM Matching: v technologies
- [Emisphere Announces Recruitment Phase III Study for Oral Osteoarthritis Treatment](#)
KSLA: Sep 22 2008 10:33PM Matching: v technologies
- [Emisphere Announces Recruitment Phase III Study for Oral Osteoarthritis Treatment](#)
KLFY: Sep 22 2008 3:14PM Matching: v technologies

V.I. Technologies Incorporated Patents:



- 6774123- [Methods and compositions for inactivating viruses](#)
- 6093564- [Methods and compositions for the selective modification of nucleic acids](#)
- 6114108- [Methods and compositions for the selective modification of viral nucleic acids](#)
- 6215003- [Synthesis of ethyleneimine dimer](#)
- 6352695- [Methods and compositions for the selective modification of nucleic acids](#)
- 6369048- [Methods and compositions for inactivating viruses](#)
- 6617100- [Solid phase quenching systems](#)
- 6617157- [Methods and compositions for the selective modification of nucleic acids](#)
- 6642033- [Nucleic acids for detecting parvovirus and methods of using same](#)
- 6750025- [Method of detecting and isolating prion protein and variants thereof](#)
- 5713891- [Modified solder for delivery of bioactive substances and methods of use thereof](#)

BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's relate service indepth.

The annual cost is \$495.00 for established organizations and \$295.00 for organizations less than 12 months old.

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2008 - BioPortfolio Limited.

